Animal Tumor Models

项目总结 动物肿瘤模型共享资源(ATM-SR)提供三个主要领域的服务：(1)转基因 以及(Ii)临床前肿瘤学，以及(Iii)动物组织病理学服务。的主要目标是 ATM-SR是为了促进斯坦福癌症研究所(SCI)进行的与癌症相关的高影响力研究 会员通过提供最先进和全面的动物资源。转基因和基因敲除 斯坦福大学于1996年成立了老鼠生产服务公司，总体目标是提供 以成本价向斯坦福大学调查人员提供转基因小鼠模型和相关支持技术- 有效税率。临床前肿瘤学服务，包括研究设计、肿瘤诱导、给药、PK 和PD研究，即数据收集和分析，由SCI于2007年发起。这些服务由 转基因、基因敲除与肿瘤模型中心(TKTC)兽医服务中心(VSC) 比较医学系管理共享的动物组织病理学服务部分 资源。主要服务包括通过组织学、免疫组织化学和病理学进行肿瘤分析 释义。自上次审查以来，动物组织实验室经历了一次重大翻新和 扩张。2020年，45%的用户是SCI调查人员。来自所有节目的会员经常使用自动取款机- SR，使用最多的是癌症生物学、癌症干细胞和癌症治疗 程序。自2015年以来，ATM-SR发表了17篇以癌症为重点的SCI成员出版物；其中10篇 它们具有很高的影响力。ATM-SR的年度预算是1,250,002美元，而CCSG的请求是105,312美元。 因此，ATM-SR利用了广泛的机构支持，只从CCSG基金中寻求8%的资金。这个 ATM-SR专注于三个主要的科学目标：(1)生产转基因和基因敲除小鼠，(2)提供 临床前肿瘤学模型服务；(3)提供组织病理学服务。

PROJECT SUMMARY The Animal Tumor Models Shared Resource (ATM-SR) provides services in three major areas: (i) transgenic and knockout mice, (ii) preclinical oncology, and (iii) animal histopathology services. The primary goal of the ATM-SR is to facilitate high-impact cancer-relevant research done by Stanford Cancer Institute (SCI) members by providing state-of-the-art and comprehensive animal resources. The transgenic and knockout mouse production services were established at Stanford in 1996 with the overall objective of providing genetically modified mouse models and associated supporting technologies to Stanford investigators at cost- effective rates. Preclinical oncology services, including study design, tumor induction, drug administration, PK and PD study, data collection and analysis, were initiated by the SCI in 2007. These services are provided by the Transgenic, Knockout and Tumor Model Center (TKTC). The Veterinary Service Center (VSC) in the Department of Comparative Medicine manages the animal histopathology service component of the shared resource. Major services include tumor analysis by histology, immunohistochemistry and pathological interpretation. Since the last review, the animal histology laboratory underwent a major renovation and expansion. In 2020, 45% of users were SCI investigators. Members from all programs regularly use the ATM- SR, with the heaviest use coming from the Cancer Biology and Cancer Stem Cells and Cancer Therapeutics programs. The ATM-SR contributed to over 17 cancer-focused SCI member publications since 2015; 10 of them were high-impact. The annual budget of the ATM-SR is $1,250,002 yet the CCSG request is $105,312. Accordingly, the ATM-SR leverages extensive institutional support and seeks only 8% from CCSG funds. The ATM-SR is focused on three major scientific aims: (1) to produce transgenic and knockout mice, (2) to provide preclinical oncology model services, and (3) to provide histopathology services.